/
OLMA
$12.20+$0.81 (+7.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$994.9M
87M shares
52-week range
$4.12 – $36.26
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-15.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $8.2K | $9.0K | $11.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$8.2K | −$9.0K | −$11.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.7M | $3.9M | $13.7M | $51.1M | $82.3M | $86.1M | $124.5M | $157.7M |
| Operating income | −$2.1M | −$4.3M | −$21.5M | −$71.5M | −$107.0M | −$105.0M | −$142.3M | −$178.7M |
| EBITDA | −$2.1M | −$4.3M | −$21.5M | −$70.9M | −$104.4M | −$96.3M | −$129.1M | −$162.0M |
| Net income | −$2.2M | −$4.3M | −$22.1M | −$71.1M | −$104.8M | −$96.7M | −$129.5M | −$162.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.16 | -0.11 | -0.58 | -1.79 | -2.62 | -2.14 | -2.20 | -1.87 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-2.22 | $-2.32–$-2.15 | 7 |
| 2027 | $23M | $-2.45 | $-2.81–$-2.28 | 7 |
| 2028 | $132M | $-1.85 | $-2.79–$-1.00 | 4 |
| 2029 | $295M | $-1.09 | $-1.83–$-0.45 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.49
Price
$12.20
Implied downside
-96%
Peer comparison
Olema Pharmaceuticals, Inc. Common Stock
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
www.olema.com- Employees
- 137
- IPO / List date
- Nov 19, 2020
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds OLMA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 25,067 | $626.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OLMA yet.
